Risk factors for hilar cholangiocarcinoma: A case-control study in China

World Journal of Gastroenterology

Volumn 17, Issue 2, 2011, Pages 249-253

  Cai, Wen Ke ^a   Sima, Hui ^a   Chen, Ben Dong ^a   Yang, Guang Shun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Choledocholithia sis; Hepatitis B virus; Hepatitis C virus; Hilar cholangiocarcinoma; Liver fuke

Indexed keywords

ADULT; AGED; ALCOHOL LIVER DISEASE; ARTICLE; ASCARIASIS; BILE DUCT CARCINOMA; BILE DUCT STONE; CHINA; CHOLECYSTECTOMY; CHOLELITHIASIS; COMMON BILE DUCT STONE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FASCIOLA HEPATICA; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOBILIARY SYSTEM; HILAR CHOLANGIOCARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SCHISTOSOMIASIS; SMOKING; ULCERATIVE COLITIS; VIRUS INFECTION;

EID: 79955767244     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i2.249     Document Type: Article

References (40)

1. Gatselis NK, Tepetes K, Loukopoulos A, Vasiou K, Zafriou A, Gioti C, Dalekos GN. Hepatitis B virus and intrahepatic cholangiocarcinoma. Cancer Invest 2007; 25: 55-58
2. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626
3. Kuroki T, Tajima Y, Kanematsu T. Hepatolithiasis and in-trahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms. J Hepatobiliary Pancreat Surg 2005; 12: 463-466
4. Wahab MA, Mostafa M, Salah T, Fouud A, Kandeel T, Elshobary M, Allah OFA, Elghawalby N, Sultan A, Ezzat F. Epidemiology of hilar cholangiocarcinoma in Egypt: single center study. Hepatogastroenterology 2007; 54: 1626-1631
5. Chow WH, Johansen C, Gridley G, Mellemkjaer L, Olsen JH, Fraumeni JF. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79: 640-644
6. Ekbom A, Hsieh CC, Yuen J, Trichopoulos D, McLaughlin JK, Lan SJ, Adami HO. Risk of extrahepatic bileduct cancer after cholecystectomy. Lancet 1993; 342: 1262-1265
7. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepa-tol 2007; 5: 1221-1228
8. Blum HE, Stowring L, Figus A, Montgomery CK, Haase AT, Vyas GN. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. Proc Natl Acad Sci USA 1983; 80: 6685-6688
9. Zhou HB, Wang H, Zhou DX, Wang H, Wang Q, Zou SS, Hu HP. Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World J Gastroenterol 2010; 16: 881-885
10. Hsing AW, Zhang M, Rashid A, McGlynn KA, Wang BS, Niwa S, Ortiz-Conde BA, Goedert JJ, Fraumeni JF Jr, O'Brien TR, Gao YT. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122: 1849-1853
11. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis 2001; 5: 191-218
12. Chen RF, Li ZH, Zou SQ, Chen JS. Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 71-74
13. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, Martelli C, Savio A, Trevisi P, Nardi G. Intrahepatic chol-angiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12: 959-964
14. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Murashima N, Chayama K, Kumada H. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88: 2471-2477
15. Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M. Hepatitis C and hepatitis B nucleic acids are present in intrahe-patic cholangiocarcinomas from the United States. Hum Pathol 2006; 37: 1211-1216
16. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, Kwon S, Lee SK, Seo DW, Kim MH, Suh DJ. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008; 103: 1716-1720
17. Akai PS, Pungpak S, Chaicumpa W, Viroj K, Bunnag D, Be-fus AD. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangio-carcinoma. Trans R Soc Trop Med Hyg 1994; 88: 471-474
18. Watanapa P, Watanapa WB. Liver fluke-associated cholan-giocarcinoma. Br J Surg 2002; 89: 962-970
19. Andoh H, Yasui O, Kurokawa T, Sato T. Cholangiocarcinoma coincident with schistosomiasis japonica. J Gastroenterol 2004; 39: 64-68
20. Wani NA, Chrungoo RK. Biliary ascariasis: surgical aspects. World J Surg 1992; 16: 976-979
21. Choi D, Lim JH, Lee KT, Lee JK, Choi SH, Heo JS, Choi DW, Jang KT, Lee NY, Kim S, Hong ST. Gallstones and Clonorchis sinensis infection: a hospital-based case-control study in Korea. J Gastroenterol Hepatol 2008; 23: e399-e404
22. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramool-sinsap C, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES, Brockelman WY. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985; 89: 151-156
23. Choi D, Lim JH, Lee KT, Lee JK, Choi SH, Heo JS, Jang KT, Lee NY, Kim S, Hong ST. Cholangiocarcinoma and Clonor-chis sinensis infection: a case-control study in Korea. J Hepatol 2006; 44: 1066-1073
24. Iida F, Iida R, Kamijo H, Takaso K, Miyazaki Y, Funabashi W, Tsuchiya K, Matsumoto Y. Chronic Japanese schistosomiasis and hepatocellular carcinoma: ten years of follow-up in Ya-manashi Prefecture, Japan. Bull World Health Organ 1999; 77: 573-581
25. Matsuda M, Fujii H. Chronic schistosomiasis japonica is an independent adverse prognostic factor for survival in hepa-tocellular carcinoma patients who have undergone hepatic resection: clinicopathological and prognostic analysis of 198 consecutive patients. World J Surg 2009; 33: 2644-2650
26. Abdel-Rahim AY. Parasitic infections and hepatic neoplasia. Dig Dis 2001; 19: 288-291
27. Haswell-Elkins MR, Sithithaworn P, Mairiang E, Elkins DB, Wongratanacheewin S, Kaewkes S, Mairiang P. Immune responsiveness and parasite-specifc antibody levels in human hepatobiliary disease associated with Opisthorchis viverrini infection. Clin Exp Immunol 1991; 84: 213-218
28. Satarug S, Haswell-Elkins MR, Tsuda M, Mairiang P, Si-thithaworn P, Mairiang E, Esumi H, Sukprasert S, Yongva-nit P, Elkins DB. Thiocyanate-independent nitrosation in humans with carcinogenic parasite infection. Carcinogenesis 1996; 17: 1075-1081
29. Thamavit W, Pairojkul C, Tiwawech D, Shirai T, Ito N. Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver. Cancer Lett 1994; 78: 121-125
30. Satarug S, Lang MA, Yongvanit P, Sithithaworn P, Mairiang E, Mairiang P, Pelkonen P, Bartsch H, Haswell-Elkins MR. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, opisthorchiasis viverrini. Cancer Epidemiol Biomarkers Prev 1996; 5: 795-800
31. Jarnagin W, Winston C. Hilar cholangiocarcinoma: diagnosis and staging. HPB (Oxford) 2005; 7: 244-251
32. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008; 42: 178-190
33. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-206
34. Broomé U, Olsson R, Lööf L, Bodemar G, Hultcrantz R, Dan-ielsson A, Prytz H, Sandberg-Gertzén H, Wallerstedt S, Lind-berg G. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615
35. Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kol-mannskog F. Risk factors in primary sclerosing cholangitis. J Hepatol 1994; 21: 1061-1066
36. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526
37. Parker RG, Kendall EJ. The liver in ulcerative colitis. Br Med J 1954; 2: 1030-1032
38. Converse CF, Reagan JW, DeCosse JJ. Ulcerative colitis and carcinoma of the bile ducts. Am J Surg 1971; 121: 39-45
39. Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48 Suppl 1: S38-S57
40. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 7-11